Centre for Neurology Studies
Surrey, British Columbia, V3V 0C6, Canada
NCT Number: NCT05112003
A growing body of evidence suggests that translingual neurostimulation (TLNS) plays a role in modulating neuroplastic changes in the brain, which has far-reaching implications for its ability to facilitate other therapeutic interventions such as cognitive processing therapy (CPT) for post-traumatic stress disorder (PTSD). The present study aims to assess the feasibility of combining TLNS with CPT in individuals with PTSD.
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Not applicable
Surrey, British Columbia, V3V 0C6, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
13.1. Requires the use of hearing aids or a cochlear implant 13.2. Diagnosed with tinnitus that is currently active 13.3. Has temporary damage to earing (e.g. punctured ear drum) 13.4. Unable to detect a 740Hz tone played at 85dB in both ears. 13.5. Implanted pacemaker or implanted electrical stimulators 13.6. Metal or plastic implants in the skull, excluding dental/facial implants 13.7. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin) 13.8. Previous exposure to the NeuroCatch™ Platform audio sequences in the last 3 months
14.1. Current disease or sensitivity of the oral cavity 14.2. History of oral cancer 14.3. Oral surgery within three months of screening 14.4. Oral cavity piercings that could interfere with PoNSTM use 14.5. Sensitivity to Nickel, Copper, or Gold 14.6. Currently enrolled in a PoNSTM treatment program or use of the PoNSTM device in the last 5 weeks 14.7. History of penetrating brain injuries 14.8. History of neurodegenerative diseases 14.9. Chronic infectious disease 14.10. Unmanaged hypertension 14.11. Diabetes 14.12. History of seizures
The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
Time frame: Baseline to week 6
Reach (RE-AIM framework)
Time frame: Change from baseline to week 6
Effectiveness (RE-AIM framework)
Time frame: Change from baseline to week 6
Effectiveness (RE-AIM framework)
Time frame: Baseline to Week 6
Adoption (RE-AIM framework)
Time frame: Baseline to week 6
Adoption (RE-AIM framework); 5-point Likert scale for participants and therapists
Time frame: Baseline to week 6
Implementation (RE-AIM framework)
Time frame: Change from baseline to week 6
Using the NeuroCatchTM Platform - EEG amplitudes
Time frame: Change from baseline to week 6
Using the NeuroCatchTM Platform - EEG latencies
Time frame: Change from baseline to week 6
Anxiety symptom severity self-report measure
Time frame: Change from baseline to week 6
Depression symptom severity self-report measure
Time frame: Change from baseline to week 6
PTSD-related functional impairment in the prior 30 days
Time frame: Change from baseline to week 6
Assesses two dimensions of meaning in life using 10 items rated on a seven-point scale
Time frame: Baseline
Time since traumatic event (years)
HealthTech Connex Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05512143
Cardiovascular Diseases, Hypertension
Providence, Rhode Island, United States
View Trial DetailsNCT03194386
Mental Disorders, Post-traumatic Stress Disorder
Bordeaux, France
View Trial DetailsNCT03519789
Mental Disorders, Post-traumatic Stress Disorder
Lille, France
View Trial DetailsNCT00739765
Anxiety Disorders, Mental Disorders
New York, United States
View Trial Details